Innoblative

Innoblative Designs, Inc. is a private medical device company established in 2014, dedicated to creating advanced-energy surgical solutions for breast cancer and other soft tissue diseases. The company focuses on addressing unmet clinical needs in early-stage breast cancer treatment by developing innovative technologies that enhance patient outcomes and surgical care. The flagship product, the SIRA® RFA Electrosurgical Device, has received U.S. FDA Investigational Device Exemption (IDE) approval. This device is designed to assist in breast-conserving surgery (BCS) by treating residual cancer in surrounding tissue during the initial lumpectomy. The technology aims to minimize or eliminate the need for subsequent radiation therapy or reoperations, providing a more patient-friendly treatment option. Innoblative's services include the development, clinical evaluation, and commercialization of the SIRA® device. The company is preparing to launch a U.S. feasibility study to assess the safety and effectiveness of the device in breast cancer patients undergoing BCS. Its primary customers are healthcare providers and institutions involved in breast cancer treatment, including surgeons and oncologists.

• Employees 12
• Founded 2013
• Total Funding $8201625